Orca Investment Management LLC Takes Position in Eli Lilly and Company $LLY

Orca Investment Management LLC purchased a new position in shares of Eli Lilly and Company (NYSE:LLY) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 1,857 shares of the company’s stock, valued at approximately $1,448,000. Eli Lilly and Company accounts for about 1.3% of Orca Investment Management LLC’s investment portfolio, making the stock its 27th largest position.

A number of other large investors also recently bought and sold shares of the stock. Hobbs Wealth Management LLC boosted its holdings in shares of Eli Lilly and Company by 0.8% during the first quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company’s stock valued at $1,205,000 after acquiring an additional 12 shares during the period. Hixon Zuercher LLC grew its position in Eli Lilly and Company by 0.7% in the 1st quarter. Hixon Zuercher LLC now owns 1,789 shares of the company’s stock worth $1,477,000 after purchasing an additional 12 shares during the last quarter. O Brien Wealth Partners LLC grew its position in Eli Lilly and Company by 25.5% in the 1st quarter. O Brien Wealth Partners LLC now owns 59 shares of the company’s stock worth $49,000 after purchasing an additional 12 shares during the last quarter. Ascent Capital Management LLC grew its position in Eli Lilly and Company by 2.5% in the 1st quarter. Ascent Capital Management LLC now owns 495 shares of the company’s stock worth $409,000 after purchasing an additional 12 shares during the last quarter. Finally, Tennessee Valley Asset Management Partners grew its position in Eli Lilly and Company by 2.7% in the 1st quarter. Tennessee Valley Asset Management Partners now owns 493 shares of the company’s stock worth $407,000 after purchasing an additional 13 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insiders Place Their Bets

In other Eli Lilly and Company news, CEO David A. Ricks bought 1,632 shares of the company’s stock in a transaction that occurred on Tuesday, August 12th. The shares were acquired at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the acquisition, the chief executive officer directly owned 546,601 shares of the company’s stock, valued at $352,431,926.77. This trade represents a 0.30% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, Director Gabrielle Sulzberger bought 117 shares of the company’s stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average price of $641.18 per share, for a total transaction of $75,018.06. Following the completion of the acquisition, the director directly owned 2,703 shares in the company, valued at approximately $1,733,109.54. This represents a 4.52% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 4,514 shares of company stock worth $2,894,841. Company insiders own 0.14% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on LLY shares. DZ Bank upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 14th. UBS Group lowered their target price on Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. Guggenheim lifted their price objective on shares of Eli Lilly and Company from $875.00 to $948.00 and gave the company a “buy” rating in a research note on Wednesday. JPMorgan Chase & Co. cut their price objective on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating on the stock in a research note on Tuesday, September 16th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Eli Lilly and Company in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $948.06.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $833.08 on Monday. The stock has a fifty day moving average price of $742.42 and a two-hundred day moving average price of $765.55. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The firm has a market cap of $788.47 billion, a P/E ratio of 54.45, a PEG ratio of 1.18 and a beta of 0.47. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $937.00.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. The firm had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.Eli Lilly and Company’s revenue was up 37.6% compared to the same quarter last year. During the same period in the previous year, the company earned $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.